Global Viscosupplementation Market by End-use (Hospitals, Orthopedic Clinics/ASCs), by Product (Five Injection, Three, Single) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global viscosupplementation market was valued at USD 3.76 Billion in 2020. It is projected to grow at a compound annual rate (CAGR of 9.37%) between 2021 and 2028. Market growth is expected to be driven by the increasing demand for nonsurgical osteoarthritis treatments, the rise in lifestyle-induced diseases, and the advancements in hyaluronic-based therapies. The market's viscosupplements have been clinically proven to be most effective in treating knee osteoarthritis. Osteoarthritis, a degenerative joint disease that causes chronic pain and disability, is the most common cause of chronic disability. The condition usually develops after age 30. It may eventually progress into a disability after 10 year.
According to the WHO, the global 65-year-old population is expected to rise from 7% in 2000, to 16% by 2050. This will cause an increase in obesity and osteoarthritis. The forecast period will see a significant increase in product demand due to the growing popularity of alternative treatments for joint pain management and the increasing global population.
Globally, the reimbursement system is expected to improve making osteoarthritis treatment affordable. The FDA has approved products such as Synvisc and Supartz Hyalgan as medical devices of Class III to treat OA knee pain. They are also reimbursed by Medicaid and Medicare. France has a clearly defined reimbursement policy for viscosupplements. Social Security reimburses 12 of the 13 products that are available in France for treatment of knee osteoarthritis. The key players will benefit from favorable reimbursement policies that cater to the elderly population.
Impact of COVID-19 on the viscosupplementation markets: 3.0% decrease from 2019 to 2020
|
Pandemic Impact |
Outlook after COVID |
|
Market was adversely affected by senior citizens who are the largest consumers of viscosupplementation products. This demographic was asked to stay at home in order to lower the risk of infection. |
COVID-19 restrictions are unlikely to affect surgery volumes. By the end of June 2020, the U.S., China and Germany had begun to recover their surgery volumes. |
|
The mass termination of elective surgery in hospitals led to a drop in sales of viscosupplementation product sales, resulting in significant losses for the manufacturers. Anika Therapeutics' total revenue fell by 13% during the second quarter 2020. |
Viscosupplementation products will continue to grow as more osteoarthritis surgeries are performed. |
Recent advancements in R&D of product pipeline provide additional opportunities for the expansion of the market for viscosupplementation. Bone Therapeutics S.A., for example, completed clinical tests in April 2018 for its intra-articular injection JTA-004 for knee OA. Market is also seeing new products that deliver better results. Anika Therapeutics, Inc., for instance, presented its Hyalofast, a hyaluronic-based scaffold to repair cartilages, at the International Cartilage Regeneration and Joint Preservation Society in June 2019.
Product Insights
The market can be divided by product into three types: single injection, three injections and five injections. With a revenue share exceeding 45%, single-injection was the most dominant product segment in 2020. Although the five- and three-injection hyaluronic acids viscosupplements are well-established, the single-injection products have just recently become popular. The market has been dominated by multiple three-injection hyaluronic acid viscosupplements for over 20 years. They have a large share of global sales. To avoid total knee replacement surgery, medical professionals prefer three injections.
The segment's growth is likely to be influenced by an increasing number of FDA approvals of three-injection viscosupplements. TriVisc was launched by OrthogenRx in the U.S. in January 2018. The shorter treatment regimen, lower hospital visits and associated pain will all contribute to the increased demand for single-injection products. MONOVISC by Anika Therapeutics was approved by the FDA in early 2014.
End-use Insights
The market can be divided into two segments based on end-use: hospitals and orthopedic clinics/ Ambulatory Surgical Centres (ASCs). ASCs/Orthodic Clinics held the largest market share at 61% in 2020. This segment is expected to see the fastest CAGR due to high demand for outpatient surgery. ASCs are outpatient surgical centers that offer same-day care. They also provide preventive (surgical) or diagnostic procedures.
ASCs are able to perform same-day surgery for ACL, hip, knee and shoulder replacements. These procedures are simpler and do not require hospitalization. Orthopedic clinics focus on the treatment of the musculoskeletal and musculoskeletal systems. This includes treating surgical and nonsurgical issues involving joints, bones and ligaments, muscles and spines, as well as nerves. This segment is expected to grow due to an increase in osteoarthritis in the elderly.
Viscosupplementation can be performed in an outpatient setting at hospitals. The patient will feel better within a few hours. A hospital will usually recommend that a surgeon or an orthopedist perform any viscosupplementation procedure. Patients prefer hospitals, especially in developing countries that lack orthopedic clinics. Patients are required to attend a hospital on a particular day in these countries where the orthopedic doctor is often a visiting faculty. Viscosupplementation is an option offered by most multispecialty hospitals around the world. This does not require additional investment.
Regional Insights
Asia Pacific had the highest revenue share at more than 45% in 2020. This is due to the large geriatric population that is more vulnerable to diseases such as osteoarthritis. Europe will see the highest CAGR over the forecast period, due to factors such as the increasing geriatric population, and increased investment by market players.
Every year, more than 2.5 million French and British women are affected by osteoporosis. The Caisse Primaire d’Assurance Maladie will cover 70% of the cost of scanning, according to the Haute Autorite de Sante. Haute Autorite de Sante, a health care body, has also recommended BONVIVA (a medicine that is prescribed in the U.K to increase bone strength). The Caisse Primaire d'Assurance Maladie will reimburse 65%.
The market is driven by a growing preference for quick treatment and the increasing prevalence of target diseases such as osteoarthritis. The most profitable use of Hyaluronic Acid was for osteoarthritis management. A single-injection cycle is expected to show the most consistent growth, because it provides convenience over its three- or five-injection counterparts.
Market Share Insights & Key Companies
To increase their market share, key players are launching new products or merging & acquiring other companies. Bioventus, for example, approved FDA approval in 2017 of DUROLANE. This single-injection HA product is used to treat knee osteoarthritis pain. After being marketed, the product was sold in over 25 countries. The following are some of the major players in the global market for viscosupplementation:
-
Sanofi
-
Anika Therapeutics, Inc.
-
Seikagaku Corp.
-
Zimmer Biomet
-
Smith & Nephew PLC
-
Ferring Pharmaceuticals B.V.
-
Lifecore Biomedical
-
LG Life Sciences Ltd.
-
Fidia Farmaceutici S.p.A
-
F.Hoffmann-La Roche Ltd.
Up Market Research published a new report titled “Viscosupplementation Market research report which is segmented by End-use (Hospitals, Orthopedic Clinics/ASCs), by Product (Five Injection, Three, Single), By Players/Companies Zimmer Biomet, Sanofi, Anika Therapeutics Inc, Smith & Nephew PLC, FHoffmann-La Roche Ltd, Fidia Farmaceutici SpA, Lifecore Biomedical, Ferring Pharmaceuticals BV, Seikagaku Corp, LG Life Sciences Ltd”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Viscosupplementation Market Research Report |
| By End-use | Hospitals, Orthopedic Clinics/ASCs |
| By Product | Five Injection, Three, Single |
| By Companies | Zimmer Biomet, Sanofi, Anika Therapeutics Inc, Smith & Nephew PLC, FHoffmann-La Roche Ltd, Fidia Farmaceutici SpA, Lifecore Biomedical, Ferring Pharmaceuticals BV, Seikagaku Corp, LG Life Sciences Ltd |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 213 |
| Number of Tables & Figures | 150 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Viscosupplementation Market Report Segments:
The market is segmented by End-use (Hospitals, Orthopedic Clinics/ASCs), by Product (Five Injection, Three, Single).
Viscosupplementation Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Viscosupplementation Market
Overview of the regional outlook of the Viscosupplementation Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Viscosupplementation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Viscosupplementation Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Hospitals
2. Orthopedic Clinics/ASCs
7. By Product:1. Five Injection
2. Three
3. Single
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viscosupplementation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Viscosupplementation Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viscosupplementation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viscosupplementation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viscosupplementation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viscosupplementation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viscosupplementation Market Size & Forecast, 2018-2028
4.5.1 Viscosupplementation Market Size and Y-o-Y Growth
4.5.2 Viscosupplementation Market Absolute $ Opportunity
Chapter 5 Global Viscosupplementation Market Analysis and Forecast by End-use
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End-use
5.1.2 Basis Point Share (BPS) Analysis by End-use
5.1.3 Absolute $ Opportunity Assessment by End-use
5.2 Viscosupplementation Market Size Forecast by End-use
5.2.1 Hospitals
5.2.2 Orthopedic Clinics/ASCs
5.3 Market Attractiveness Analysis by End-use
Chapter 6 Global Viscosupplementation Market Analysis and Forecast by Product
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product
6.1.2 Basis Point Share (BPS) Analysis by Product
6.1.3 Absolute $ Opportunity Assessment by Product
6.2 Viscosupplementation Market Size Forecast by Product
6.2.1 Five Injection
6.2.2 Three
6.2.3 Single
6.3 Market Attractiveness Analysis by Product
Chapter 7 Global Viscosupplementation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viscosupplementation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Viscosupplementation Analysis and Forecast
9.1 Introduction
9.2 North America Viscosupplementation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Viscosupplementation Market Size Forecast by End-use
9.6.1 Hospitals
9.6.2 Orthopedic Clinics/ASCs
9.7 Basis Point Share (BPS) Analysis by End-use
9.8 Absolute $ Opportunity Assessment by End-use
9.9 Market Attractiveness Analysis by End-use
9.10 North America Viscosupplementation Market Size Forecast by Product
9.10.1 Five Injection
9.10.2 Three
9.10.3 Single
9.11 Basis Point Share (BPS) Analysis by Product
9.12 Absolute $ Opportunity Assessment by Product
9.13 Market Attractiveness Analysis by Product
Chapter 10 Europe Viscosupplementation Analysis and Forecast
10.1 Introduction
10.2 Europe Viscosupplementation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Viscosupplementation Market Size Forecast by End-use
10.6.1 Hospitals
10.6.2 Orthopedic Clinics/ASCs
10.7 Basis Point Share (BPS) Analysis by End-use
10.8 Absolute $ Opportunity Assessment by End-use
10.9 Market Attractiveness Analysis by End-use
10.10 Europe Viscosupplementation Market Size Forecast by Product
10.10.1 Five Injection
10.10.2 Three
10.10.3 Single
10.11 Basis Point Share (BPS) Analysis by Product
10.12 Absolute $ Opportunity Assessment by Product
10.13 Market Attractiveness Analysis by Product
Chapter 11 Asia Pacific Viscosupplementation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Viscosupplementation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Viscosupplementation Market Size Forecast by End-use
11.6.1 Hospitals
11.6.2 Orthopedic Clinics/ASCs
11.7 Basis Point Share (BPS) Analysis by End-use
11.8 Absolute $ Opportunity Assessment by End-use
11.9 Market Attractiveness Analysis by End-use
11.10 Asia Pacific Viscosupplementation Market Size Forecast by Product
11.10.1 Five Injection
11.10.2 Three
11.10.3 Single
11.11 Basis Point Share (BPS) Analysis by Product
11.12 Absolute $ Opportunity Assessment by Product
11.13 Market Attractiveness Analysis by Product
Chapter 12 Latin America Viscosupplementation Analysis and Forecast
12.1 Introduction
12.2 Latin America Viscosupplementation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Viscosupplementation Market Size Forecast by End-use
12.6.1 Hospitals
12.6.2 Orthopedic Clinics/ASCs
12.7 Basis Point Share (BPS) Analysis by End-use
12.8 Absolute $ Opportunity Assessment by End-use
12.9 Market Attractiveness Analysis by End-use
12.10 Latin America Viscosupplementation Market Size Forecast by Product
12.10.1 Five Injection
12.10.2 Three
12.10.3 Single
12.11 Basis Point Share (BPS) Analysis by Product
12.12 Absolute $ Opportunity Assessment by Product
12.13 Market Attractiveness Analysis by Product
Chapter 13 Middle East & Africa (MEA) Viscosupplementation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by End-use
13.6.1 Hospitals
13.6.2 Orthopedic Clinics/ASCs
13.7 Basis Point Share (BPS) Analysis by End-use
13.8 Absolute $ Opportunity Assessment by End-use
13.9 Market Attractiveness Analysis by End-use
13.10 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by Product
13.10.1 Five Injection
13.10.2 Three
13.10.3 Single
13.11 Basis Point Share (BPS) Analysis by Product
13.12 Absolute $ Opportunity Assessment by Product
13.13 Market Attractiveness Analysis by Product
Chapter 14 Competition Landscape
14.1 Viscosupplementation Market: Competitive Dashboard
14.2 Global Viscosupplementation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Zimmer Biomet
14.3.2 Sanofi
14.3.3 Anika Therapeutics Inc
14.3.4 Smith & Nephew PLC
14.3.5 FHoffmann-La Roche Ltd
14.3.6 Fidia Farmaceutici SpA
14.3.7 Lifecore Biomedical
14.3.8 Ferring Pharmaceuticals BV
14.3.9 Seikagaku Corp
14.3.10 LG Life Sciences Ltd
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viscosupplementation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viscosupplementation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viscosupplementation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viscosupplementation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viscosupplementation Market Size & Forecast, 2018-2028
4.5.1 Viscosupplementation Market Size and Y-o-Y Growth
4.5.2 Viscosupplementation Market Absolute $ Opportunity
Chapter 5 Global Viscosupplementation Market Analysis and Forecast by End-use
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End-use
5.1.2 Basis Point Share (BPS) Analysis by End-use
5.1.3 Absolute $ Opportunity Assessment by End-use
5.2 Viscosupplementation Market Size Forecast by End-use
5.2.1 Hospitals
5.2.2 Orthopedic Clinics/ASCs
5.3 Market Attractiveness Analysis by End-use
Chapter 6 Global Viscosupplementation Market Analysis and Forecast by Product
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product
6.1.2 Basis Point Share (BPS) Analysis by Product
6.1.3 Absolute $ Opportunity Assessment by Product
6.2 Viscosupplementation Market Size Forecast by Product
6.2.1 Five Injection
6.2.2 Three
6.2.3 Single
6.3 Market Attractiveness Analysis by Product
Chapter 7 Global Viscosupplementation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viscosupplementation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Viscosupplementation Analysis and Forecast
9.1 Introduction
9.2 North America Viscosupplementation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Viscosupplementation Market Size Forecast by End-use
9.6.1 Hospitals
9.6.2 Orthopedic Clinics/ASCs
9.7 Basis Point Share (BPS) Analysis by End-use
9.8 Absolute $ Opportunity Assessment by End-use
9.9 Market Attractiveness Analysis by End-use
9.10 North America Viscosupplementation Market Size Forecast by Product
9.10.1 Five Injection
9.10.2 Three
9.10.3 Single
9.11 Basis Point Share (BPS) Analysis by Product
9.12 Absolute $ Opportunity Assessment by Product
9.13 Market Attractiveness Analysis by Product
Chapter 10 Europe Viscosupplementation Analysis and Forecast
10.1 Introduction
10.2 Europe Viscosupplementation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Viscosupplementation Market Size Forecast by End-use
10.6.1 Hospitals
10.6.2 Orthopedic Clinics/ASCs
10.7 Basis Point Share (BPS) Analysis by End-use
10.8 Absolute $ Opportunity Assessment by End-use
10.9 Market Attractiveness Analysis by End-use
10.10 Europe Viscosupplementation Market Size Forecast by Product
10.10.1 Five Injection
10.10.2 Three
10.10.3 Single
10.11 Basis Point Share (BPS) Analysis by Product
10.12 Absolute $ Opportunity Assessment by Product
10.13 Market Attractiveness Analysis by Product
Chapter 11 Asia Pacific Viscosupplementation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Viscosupplementation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Viscosupplementation Market Size Forecast by End-use
11.6.1 Hospitals
11.6.2 Orthopedic Clinics/ASCs
11.7 Basis Point Share (BPS) Analysis by End-use
11.8 Absolute $ Opportunity Assessment by End-use
11.9 Market Attractiveness Analysis by End-use
11.10 Asia Pacific Viscosupplementation Market Size Forecast by Product
11.10.1 Five Injection
11.10.2 Three
11.10.3 Single
11.11 Basis Point Share (BPS) Analysis by Product
11.12 Absolute $ Opportunity Assessment by Product
11.13 Market Attractiveness Analysis by Product
Chapter 12 Latin America Viscosupplementation Analysis and Forecast
12.1 Introduction
12.2 Latin America Viscosupplementation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Viscosupplementation Market Size Forecast by End-use
12.6.1 Hospitals
12.6.2 Orthopedic Clinics/ASCs
12.7 Basis Point Share (BPS) Analysis by End-use
12.8 Absolute $ Opportunity Assessment by End-use
12.9 Market Attractiveness Analysis by End-use
12.10 Latin America Viscosupplementation Market Size Forecast by Product
12.10.1 Five Injection
12.10.2 Three
12.10.3 Single
12.11 Basis Point Share (BPS) Analysis by Product
12.12 Absolute $ Opportunity Assessment by Product
12.13 Market Attractiveness Analysis by Product
Chapter 13 Middle East & Africa (MEA) Viscosupplementation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by End-use
13.6.1 Hospitals
13.6.2 Orthopedic Clinics/ASCs
13.7 Basis Point Share (BPS) Analysis by End-use
13.8 Absolute $ Opportunity Assessment by End-use
13.9 Market Attractiveness Analysis by End-use
13.10 Middle East & Africa (MEA) Viscosupplementation Market Size Forecast by Product
13.10.1 Five Injection
13.10.2 Three
13.10.3 Single
13.11 Basis Point Share (BPS) Analysis by Product
13.12 Absolute $ Opportunity Assessment by Product
13.13 Market Attractiveness Analysis by Product
Chapter 14 Competition Landscape
14.1 Viscosupplementation Market: Competitive Dashboard
14.2 Global Viscosupplementation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Zimmer Biomet
14.3.2 Sanofi
14.3.3 Anika Therapeutics Inc
14.3.4 Smith & Nephew PLC
14.3.5 FHoffmann-La Roche Ltd
14.3.6 Fidia Farmaceutici SpA
14.3.7 Lifecore Biomedical
14.3.8 Ferring Pharmaceuticals BV
14.3.9 Seikagaku Corp
14.3.10 LG Life Sciences Ltd
Segments Covered in the Report
The global Viscosupplementation market has been segmented based on
By End-use
The global Viscosupplementation market has been segmented based on
By End-use
- Hospitals
- Orthopedic Clinics/ASCs
- Five Injection
- Three
- Single
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Zimmer Biomet
- Sanofi
- Anika Therapeutics Inc
- Smith & Nephew PLC
- FHoffmann-La Roche Ltd
- Fidia Farmaceutici SpA
- Lifecore Biomedical
- Ferring Pharmaceuticals BV
- Seikagaku Corp
- LG Life Sciences Ltd
Our Clients
Related Reports
Some other reports from this category!
